FibroGen Reports Second Quarter 2018 Financial Results
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic Cancer Conference Call Today at 5:00 p.m. Eastern Time/2:00 p …